FY2025 EPS Estimate for Verve Therapeutics Raised by Analyst

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for Verve Therapeutics in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings of ($2.16) per share for the year, up from their prior forecast of ($2.38). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $32.98 million during the quarter, compared to analysts' expectations of $7.13 million.

Other analysts have also recently issued research reports about the stock. Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Canaccord Genuity Group increased their target price on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Guggenheim lifted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, HC Wainwright raised their target price on Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a report on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $25.75.

Verve Therapeutics Trading Down 8.2%

Shares of NASDAQ VERV traded down $0.38 during trading hours on Monday, reaching $4.23. The stock had a trading volume of 2,799,371 shares, compared to its average volume of 1,856,963. The firm has a market cap of $377.07 million, a price-to-earnings ratio of -1.72 and a beta of 1.82. The firm has a 50-day moving average of $4.71 and a 200-day moving average of $5.84. Verve Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $9.31.

Institutional Investors Weigh In On Verve Therapeutics

Several institutional investors have recently modified their holdings of the company. KFG Wealth Management LLC purchased a new position in Verve Therapeutics in the 1st quarter valued at approximately $46,000. IFP Advisors Inc grew its holdings in Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after purchasing an additional 8,237 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Verve Therapeutics in the first quarter valued at $47,000. E Fund Management Co. Ltd. acquired a new position in shares of Verve Therapeutics during the 1st quarter worth $48,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics in the 4th quarter worth about $50,000. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.